CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients

Rok, strany: 2010, 512 - 521

Several polymorphisms in cytochrome P-450s (CYP)s and Glutathione S-transferases (GST)s have been reported to be associated with survival rates of patients with non-small cell lung cancer (NSCLC) but the studies in this regard are scarce and the results are contradictory. In this study, CYP1A1 (Ile462Val), CYP1B1(Asn453Ser), GST M1, GSTP1 exon 5 (Ile105Val) and exon 6(Ala114Val) and GSTT1 polymorphisms were determined in 138 patients with advanced NSCLC to evaluate their role in survival. Of the studied CYP and GST polymorphisms only GSTP1 exon 6 variant significantly altered (improved) the survival compared to wild type (p=0.036) with median survival of 22.2 months and 16.1 months, respectively. Multivariate analysis also revealed a significant reduction of adjusted hazard ratio of death associated only with the GSTP1 exon 6 variant genotype of 0.45 (95% confidence interval (95% CI), 0.23-0.89, p=0.022). These results show that the GSTP1 exon 6 variant genotype is associated with improved survival in the patients with advanced NSCLC. Keywords: Cytochrome P-450, glutathione S-transferase, non small cell lung cancer, polymorphism, survival

ISO 690:

Ada, A., C.kunak, S., Hancer, F., Bilgen, S., Suzen, S., Alpar, S., Gulhan, M., Kurt, B., Iscan, M. 2010. CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients. In NEOPLASMA, vol. 57, no.6, pp. 512-521. 0028-2685.

APA:

Ada, A., C.kunak, S., Hancer, F., Bilgen, S., Suzen, S., Alpar, S., Gulhan, M., Kurt, B., Iscan, M. (2010). CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients. NEOPLASMA, 57(6), 512-521. 0028-2685.